Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Colorectal Neoplasms 1

Interventions

fludarabine phosphate 87Cyclophosphamide 78Whole-Body Irradiation 59Azacitidine 59fludarabine 56Mycophenolic Acid 56Busulfan 53Tacrolimus 51Peripheral Blood Stem Cell Transplantation 41Melphalan 40Cytarabine 38Antilymphocyte Serum 38Filgrastim 37Granulocyte Colony-Stimulating Factor 33Cyclosporine 33Methotrexate 32Decitabine 32thymoglobulin 22Thiotepa 21Clofarabine 21Cord Blood Stem Cell Transplantation 19Stem Cell Transplantation 16Alemtuzumab 16Sirolimus 15Rituximab 15sargramostim 12Lenalidomide 12Etoposide 11Radiotherapy 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myelodysplastic Syndromes × Infusions, Intravenous × Clear all
NCT03238248 2024-11-04

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
71 enrolled 13 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡